̽»¨Ö±²¥

Researchers at the ̽»¨Ö±²¥ of Cambridge have designed antibodies that target the protein deposits in the brain associated with Alzheimer’s disease, and stop their production. 

Trevor Lawley and Gordon Dougan are bug hunters, albeit not the conventional kind. ̽»¨Ö±²¥bugs they collect are invisible to the naked eye. And even though we’re teeming with them, researchers are only beginning to discover how they keep us healthy – and how we could use these bugs as drugs.

It is almost impossible for an injured heart to fully mend itself. Within minutes of being deprived of oxygen – as happens during a heart attack when arteries to the heart are blocked – the heart’s muscle cells start to die. Sanjay Sinha wants to mend these hearts so that they work again. 

Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.

How will precision medicine define 21st-century therapeutics? What will future healthcare look like? And what actually lies ‘beyond the pill’? Professor Chris Lowe, inaugural Director of the Cambridge Academy of Therapeutic Sciences, takes the long view on the future of therapeutics.

Why do we age when we get older? Epigenetics may hold the answer – but could it one day help us turn back the clock? Professor Wolf Reik from the Department of Physiology, Development and Neuroscience at the ̽»¨Ö±²¥ of Cambridge and Dr Oliver Stegle from the European Bioinformatics Institute look at the ‘epigenetic clock’ in ̽»¨Ö±²¥Conversation.

A ̽»¨Ö±²¥ of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease. 

A team of scientists who a few years ago identified a major pathway that leads to brain cell death in mice, have now found two drugs that block the pathway and prevent neurodegeneration. ̽»¨Ö±²¥drugs caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials.

A faster and more accurate method of identifying which of an individual’s genes are associated with particular symptoms has been developed by a team of researchers from the UK and Saudi Arabia. This new approach could enable scientists to take advantage of recent developments in genome sequencing to improve diagnosis and potential treatment options.

Scientists at the ̽»¨Ö±²¥ of Cambridge and the Wellcome Trust Sanger Institute have created a new technique that simplifies the production of human brain and muscle cells - allowing millions of functional cells to be generated in just a few days. ̽»¨Ö±²¥results published today in Stem Cell Reports open the door to producing a diversity of new cell types that could not be made before in order to study disease.